EXIDEIND.NSE

Exide Industries Ltd.

Kolkata: Exide Industries reported a marginal rise in Q4 net profit to Rs 312 crore from Rs 255 crore a year ago, while revenue increased from Rs 4,15.

Battery sector stocks in India guide: battery sector growth via electric vehicles, with insights on Exide Industries and HBL Engineering for smart investing decisions.

Battery sector stocks in India guide: battery sector growth via electric vehicles, with insights on Exide Industries and HBL Engineering for smart investing decisions.

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

In this briefing: US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 1. US Semiconductor China Export Restrictions. Game, Set & Now Let's Try MATCH! On April 2, 2026, a bipartisan group of US lawmakers introduced H.R. 8170, the Multilateral Alignment of Technology Controls on Hardware Act, or the MATCH Act. Three weeks later, on April 22, the House Foreign Affairs Committee advanced it in what lawmakers called ”the largest significant export control mark-up in the history of Congress.” If enacted, the immersion DUV ban will deal a serious blow to China's semiconductor ambitions in the medium term. It will also greatly accelerate Chinese efforts to develop their own... 2. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 3.

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.

In this briefing: Exencial Industry Tidings - 27-04-2026 APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 1. Exencial Industry Tidings - 27-04-2026 Revenues of Reliance Consumer Products double to Rs.220 bln in 2025-26 Govt likely to keep prices of fertilisers unchanged, subsidy to remain high India EV market shifts toward mid-priced vehicles as entry segment declines 2. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev.

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.

In this briefing: APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear HDFC Bank (HDFCB IN) Vs. Yes Bank (YES IN): Large–Small Bank Spread Signals Statistical Arbitrage Primer: Exide Industries (EXID IN) - Apr 2026 Primer: Delta Manufacturing (DELTAMAG IN) - Apr 2026 Primer: Zen Technologies (ZEN IN) - Apr 2026 1. APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear Sino Biopharmaceutical received approval for Benmelstobart plus Anlotinib for alveolar soft part sarcoma in China. Wuxi Biologics announced that three of its manufacturing facilities received GMP certification from South Korea. Astellas Pharma has been granted Priority Review status by the FDA for indication expansion application for Padcev. Eisai’s Phase 3 trial evaluating Lenvima in RCC did not meet primary endpoints. Celltrion started patient dosing for three of its novel ADC-based anticancer drug candidates. Cochlear has reduced FY26 underlying net profit guidance to A$290–330M from A$435–460M. 2.